The PATRICIA phase II trial aimed to evaluate the efficacy of palbociclib plus trastuzumab with or without letrozole, depending on HR status, in postmenopausal pre-treated patients with HER2-positive metastatic BC. This evidence concerns the gene ERBB2 and breast cancer.